NAPISTAR 1-01: A Phase 1 dose escalation study of TUB-040, a novel NaPi2b-targeting exatecan antibody-drug conjugate in patients with platinum-resistant high grade serous ovarian carcinoma.
Year: 2026
Type: article
Study design: Clinical Trial
Authors: Jalid Sehouli, Toon Van Gorp, Elena Braicu, Shiraj Sen, Valentina Boni, Rebecca Kristeleit, Ignacio Matos Garcia, Sebastien Ochsenreither, Debra L. Richardson, Alexander Spira, Alexander Starodub, Juergen Wolf, Katrien De Graaf, Björn Hock, Guenter Fingerle-Rowson, Yariv Houvras, Ines Vasconcelos, Antonio Gonzalez-Martin
Institutions: Charité – Universitätsmedizin Berlin, KU Leuven, Hospital Universitario Quirónsalud Madrid, King's College London, Guy's and St Thomas' NHS Foundation Trust, Clinica Universidad de Navarra, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Christ Hospital, University of Cologne, Tubulis (Germany)
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129257155